23.18
+18.25(+370.18%)
Currency In USD
Address
480 Arsenal Way
Watertown, MA 02472
United States of America
Phone
617 393 4600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
30
First IPO Date
May 01, 2020
| Name | Title | Pay | Year Born |
| Dr. Maria Palasis Ph.D. | Chief Executive Officer, President & Director | 3.66M | 1965 |
| Dr. Harlan W. Waksal M.D. | Executive Chairman | 430,878 | 1953 |
| Mr. Jason Cavalier | Chief Financial Officer, Treasurer & Secretary | 1.28M | 1974 |
| Ms. Gloria Cosgrove | Senior Vice President of Quality | 0 | N/A |
| Dr. Elazer R. Edelman FACC, M.D., Ph.D. | Vice President of Finance & Risk | 0 | 1957 |
| Ms. Allison Nance | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Ms. Vineeta Belanger Ph.D. | Senior Vice President of Clinical Affairs | 0 | N/A |
| Mr. Ronan P. O'Brien J.D. | Chief Legal Officer | 0 | 1973 |
| Dr. Robert Kern M.D. | Chief Clinical Advisor | 0 | N/A |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder | 0 | 1969 |
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
